With the current price of $2, the stock of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) concluded the trading session seeing its price drop by -0.03 points or at a loss of -1.48% compared to its previous day’s closing price of $2.03. About 1.396 million shares of the stock changed hands on the day. The trading volume of MRNS’s shares during the past session compares with the stock’s average daily trading volume of 1.65 million shares. On the other hand, a float of 103 million shares and a weekly performance of 10.5% make the stock worth to keep an eye on. Analysts are in agreement on an annual target price of $0 for MRNS’s share which suggests that the stock, price of which is currently buoying between $1.945 and $2.03, is prone to a loss of -100%. But still, there are some analysts recommending a price below the agreed average price and one of them has given a target price of $4 to the stock.
The latest data released on July 31, 2020 shows that the short float in the Marinus Pharmaceuticals, Inc.’s stock is trending upward as short interest in MRNS shares climbed up leaving more number of shares available to public for trading. Number of shares shorted in the MRNS is currently comprised of 10.4% of the float as the volume of shorted shares inclined by 2389670 shares. Over the past two weeks, stock’s short interests weakened as number of shorted shares increased to 10.672 million shares from the previous figure of 8.282 million shares. Stock’s average intraday volume is now standing at 1.701 million shares which indicate that the days to cover the shorts are nearly 6.273246.
After concluding the day’s trading, price of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) is up $0.19 over the week and it is $0.2 above 20-day average price. The highest price touched by the stock on the day was lower than 52-week high price of $3.5 that was attained on 06/16/20.
The stock has traded as low as $1.01 in past 52-week, and its current price is 98.02% above from that 52-week low price mark recorded on 11/20/19, which is an indicator that could increase the investors’ motivation level in taking advantage of price surge the stock has currently been going through. Stock currently has its beta at 1.98. A beta value of more than 1 represents higher volatility of a stock than that of the market and for the reason investors closely watch the behavior of such stock.
Current indicators are pointing at 51.96 as 14-days RSI of Marinus Pharmaceuticals, Inc. This means that the MRNS is currently in a neutral territory and its share’s price movement is likely to be steady for a while. Similarly, the stochastic oscillator is indicating a momentum of 82.54%, implying stock’s share price is buoying in an oversold state.
Technical chart is showing 1st resistance point of $2.04 for the MRNS’s share while placing it at a 2nd resistance point of $2.08 to be settled at. But if the stock takes a plunge lower than the 1st support price of $1.95 then its market would become weakened. And that would likely sliding the stock price down to 2nd support price level of $1.91.
MACD oscillator is showing a reading of 0.13 for the stock which means that it is currently in the green zone. Any movement above or below the zero level of the indicator has always being noticed by the investors as it makes them compare the stock’s average measure in short-term with that in the long-term. An MACD evaluation of more than zero means that stock has a stronger short-term average than long-term average, which implies that stock’s price is likely to climb up. But an MACD below zero indicates weaker short-term average compare to the long-term average.
H.C. Wainwright maintained its Buy recommendation for MRNS stock in a review note dated July 01, but moved the price target up from $6 to $9. The stock gets a Outperform recommendation from analysts at Cowen who started covering the stock in their July 01 note to investors.Craig Hallum analysts started covering the stock with recommendation of Buy rating on April 09, while suggesting a price target of $4.5 to it.
The average rating of 1.44 for MRNS is placing the stock in bullish category at the moment. In a poll by Reuters including 9 analysts in it who kept tracking the Marinus Pharmaceuticals, Inc., 0 rated the stock as hold. Others were in different opinions for the MRNS. Out of remaining 9 analysts, 9 rated the stock as a buy or strong buy. 0 were in favor of a sell rating for the stock while advising investors to shun the stock if they already have any or otherwise not to buy it.